Evidence map›Paper›PMID 34075383›Full record

ArticlebioRxiv : the preprint server for biology2021

Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.

Antonella Scaglione, Silvana Opp, Alicia Hurtado, Ziyan Lin, Christine Pampeno, Maria G Noval, Sara A Thannickal, Kenneth A Stapleford, Daniel Meruelo

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Antonella ScaglioneDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Silvana OppDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Alicia HurtadoDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Ziyan LinDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Christine PampenoDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Maria G NovalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Sara A ThannickalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Kenneth A StaplefordDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Daniel MerueloDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
New York University · US

Funding

A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancerR44CA250627 · NCI · CYNVEC, LLC · PI MERUELO, DANIEL, SESSIONS, JENNIFER JUNE · 2020 to 2022
$2.4M
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after ChemotherapyR44CA206606 · NCI · CYNVEC, LLC · PI MERUELO, DANIEL, WINRAM, SCOTT BUDD · 2016 to 2017
$2.0M
NCI NIH HHS R44 CA206606NCI NIH HHS R44 CA250627
6 · The paper itself

Abstract

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world's population at record speeds. However, there is still demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles and metabolic analysis indicate a reprogramming of T-cells in vaccinated mice. Activated T-cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response that can be used as a new candidate to combat SARS-CoV-2. Given the strong T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as, serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens.

Indexed as

Alphavirus VaccineCOVID19SARS-CoV-2 ImmunitySARS-CoV-2 vaccineSindbis Virus VaccineSynergistic Combination SARS-CoV-2 Vaccine StrategyαOX40

Identifiers

PMID34075383
PMCPMC8168399
OpenAlexW3165280030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.